ATE355266T1 - Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen - Google Patents

Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen

Info

Publication number
ATE355266T1
ATE355266T1 AT99957636T AT99957636T ATE355266T1 AT E355266 T1 ATE355266 T1 AT E355266T1 AT 99957636 T AT99957636 T AT 99957636T AT 99957636 T AT99957636 T AT 99957636T AT E355266 T1 ATE355266 T1 AT E355266T1
Authority
AT
Austria
Prior art keywords
production
pharmaceutical compositions
compositions containing
containing same
new acylated
Prior art date
Application number
AT99957636T
Other languages
English (en)
Inventor
Jacques Bauer
Olivier Richard Martin
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Application granted granted Critical
Publication of ATE355266T1 publication Critical patent/ATE355266T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/10Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/091Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99957636T 1998-06-30 1999-06-23 Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen ATE355266T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801396 1998-06-30

Publications (1)

Publication Number Publication Date
ATE355266T1 true ATE355266T1 (de) 2006-03-15

Family

ID=9522667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957636T ATE355266T1 (de) 1998-06-30 1999-06-23 Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen

Country Status (21)

Country Link
US (2) US7157092B1 (de)
EP (1) EP1091928B1 (de)
JP (1) JP4699609B2 (de)
KR (1) KR100766016B1 (de)
CN (1) CN1168702C (de)
AR (1) AR029877A1 (de)
AT (1) ATE355266T1 (de)
AU (1) AU761396B2 (de)
BR (1) BR9911329A (de)
CA (1) CA2337807C (de)
CZ (1) CZ302062B6 (de)
DE (1) DE69935330T2 (de)
DK (1) DK1091928T3 (de)
EE (1) EE04489B1 (de)
ES (1) ES2284275T3 (de)
HU (1) HUP0102475A3 (de)
PL (1) PL195764B1 (de)
RU (1) RU2223262C2 (de)
SK (1) SK287073B6 (de)
TW (1) TWI255808B (de)
WO (1) WO2000000462A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04489B1 (et) * 1998-06-30 2005-06-15 Om Pharma Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid
WO2001046127A1 (fr) * 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
WO2002064616A2 (en) * 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
ES2335979T3 (es) 2001-09-14 2010-04-07 Cytos Biotechnology Ag Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
US7517520B2 (en) 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
EP2269638A3 (de) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzungen mit Virosomen und einem Saponin-Adjuvans
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
AU2006226458B2 (en) 2005-03-23 2012-08-30 Glaxosmithkline Biologicals S.A. Novel composition
JP5484732B2 (ja) 2005-12-14 2014-05-07 サイトス バイオテクノロジー アーゲー 過敏症の治療のための免疫賦活性核酸パッケージ粒子
EP3470080A1 (de) 2005-12-22 2019-04-17 GlaxoSmithKline Biologicals S.A. Impfstoff
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
WO2007102081A2 (en) 2006-03-09 2007-09-13 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
EP2476433A1 (de) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung
PL2032592T3 (pl) 2006-06-12 2013-11-29 Kuros Biosciences Ag Sposoby pakowania oligonukleotydów do cząstek wirusopodobnych z bakteriofagów RNA
EP2040742B1 (de) 2006-07-18 2014-10-29 GlaxoSmithKline Biologicals S.A. Malaria-impfstoffe
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
US20090263422A1 (en) 2006-09-15 2009-10-22 Emmanuel Jules Hanon Influenza vaccine
EP2086582B1 (de) 2006-10-12 2012-11-14 GlaxoSmithKline Biologicals s.a. Impfstoff mit einem öl-in-wasser-emulsionshilfsstoff
CN101675068A (zh) 2007-03-02 2010-03-17 葛兰素史密丝克莱恩生物有限公司 新的方法和组合物
AR066405A1 (es) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa Vacuna
KR20100045445A (ko) 2007-06-26 2010-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
EP2020240A1 (de) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Verfahren und Substanzen zur Behandlung von Morbus Alzheimer
EP2227483B1 (de) 2007-12-19 2017-04-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Lösliche formen von hendra- und nipah-virus-f-glycoprotein und anwendungen davon
CN101952321B (zh) 2007-12-24 2016-05-11 葛兰素史密斯克莱生物公司 重组rsv抗原
SI2271360T1 (sl) 2008-04-16 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗
WO2010079081A1 (en) 2009-01-07 2010-07-15 Glaxosmithkline Biologicals S.A. Methods for recovering a virus or a viral antigen produced by cell culture
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
JP5843615B2 (ja) 2009-02-06 2016-01-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 密度勾配超遠心分離によるウイルスまたはウイルス抗原の精製
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CA2766205A1 (en) 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
PE20121541A1 (es) 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
ES2538474T3 (es) 2009-09-25 2015-06-22 Glaxosmithkline Biologicals S.A. Ensayo de inmunodifusión para el virus de la gripe
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
WO2011101332A1 (en) 2010-02-16 2011-08-25 Proyecto De Biomedicina Cima, S.L. Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
JP6200805B2 (ja) 2010-05-03 2017-09-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規な方法
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
SG189176A1 (en) 2010-10-15 2013-05-31 Glaxosmithkline Biolog Sa Cytomegalovirus gb antigen
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
MX339058B (es) 2011-05-17 2016-05-09 Glaxosmithkline Biolog Sa Vacuna contra streptococcus pneumoniae.
BR112014023092A8 (pt) 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AR095425A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Biologicals Sa Vacuna, uso y procedimiento para prevenir una infección por picornavirus
WO2015011254A1 (en) 2013-07-26 2015-01-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2015018806A1 (en) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
ES2778928T3 (es) 2013-08-30 2020-08-12 Glaxosmithkline Biologicals Sa Producción a gran escala de virus en cultivos celulares
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015165480A1 (en) 2014-04-30 2015-11-05 Institute For Research In Biomedicine Human cytomegalovirus vaccine compositions and method of producing the same
JP6664338B2 (ja) 2014-06-13 2020-03-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組合せ物
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3313435A1 (de) 2015-06-26 2018-05-02 Institute for Research in Biomedicine Neuartige impfstoffe zur prävention und behandlung von malaria
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon
US11911553B2 (en) * 2018-07-06 2024-02-27 Fenwal, Inc. Systems and methods for concentrating cells with a syringe and a centrifuge
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN112329267B (zh) * 2020-11-26 2022-08-16 中国核动力研究设计院 一种基于特征线法的组合几何中子输运处理方法及装置
MX2023006320A (es) 2020-12-02 2023-06-14 Glaxosmithkline Biologicals Sa Cadena donante complementada fimh.
WO2022161598A1 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2022162012A2 (en) 2021-01-26 2022-08-04 Eth Zurich Antibodies broadly targeting coronaviruses and uses thereof
WO2023144665A1 (en) 2022-01-28 2023-08-03 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227586A (ja) * 1985-03-30 1986-10-09 Dai Ichi Seiyaku Co Ltd ジサツカライド誘導体およびその塩
US4746742A (en) * 1985-11-28 1988-05-24 Toho Yakuhin Kogyo Kabushiki Kaisha Analogs of nonreducing monosaccharide moiety of lipid A
DE4229877C2 (de) * 1992-09-04 1994-09-15 Max Delbrueck Centrum Phospho- bzw. Phosphono-(N-acyl)-serine und ihre Herstellung
EP0668289A4 (de) * 1993-09-07 1998-10-21 Suntory Ltd Disaccharid derivate.
BR9408071A (pt) * 1993-11-17 1996-12-24 Om Lab Sa Di-sacarideos de glucosamina processo para sua preparação e composição farmacêutica que compreende os mesmos e seu uso
EE04489B1 (et) * 1998-06-30 2005-06-15 Om Pharma Atsüülpseudodipeptiidid, nende valmistamise meetod ja neid sisaldavad farmatseutilised kompositsioonid

Also Published As

Publication number Publication date
PL345040A1 (en) 2001-11-19
EE04489B1 (et) 2005-06-15
BR9911329A (pt) 2001-10-16
JP2002519338A (ja) 2002-07-02
CA2337807C (fr) 2012-08-21
AU4284899A (en) 2000-01-17
DE69935330D1 (de) 2007-04-12
US20060148678A1 (en) 2006-07-06
CZ20004893A3 (en) 2001-05-16
EP1091928B1 (de) 2007-02-28
HUP0102475A3 (en) 2001-12-28
AR029877A1 (es) 2003-07-23
KR100766016B1 (ko) 2007-10-11
CN1168702C (zh) 2004-09-29
US7157092B1 (en) 2007-01-02
SK18872000A3 (sk) 2001-07-10
CA2337807A1 (fr) 2000-01-06
HUP0102475A2 (hu) 2001-11-28
TWI255808B (en) 2006-06-01
DE69935330T2 (de) 2007-10-31
KR20010083078A (ko) 2001-08-31
WO2000000462A1 (fr) 2000-01-06
CN1306504A (zh) 2001-08-01
CZ302062B6 (cs) 2010-09-22
DK1091928T3 (da) 2007-07-23
ES2284275T3 (es) 2007-11-01
EP1091928A1 (de) 2001-04-18
PL195764B1 (pl) 2007-10-31
RU2223262C2 (ru) 2004-02-10
SK287073B6 (sk) 2009-11-05
AU761396B2 (en) 2003-06-05
EE200000791A (et) 2002-02-15
JP4699609B2 (ja) 2011-06-15

Similar Documents

Publication Publication Date Title
ATE355266T1 (de) Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen
DE69902535D1 (de) Phenoxypropanolamin-derivate, verfahren zu ihrer herstellung und diese enthaltenden pharmazeutischen zusammensetzungen
ATE296823T1 (de) Substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE252562T1 (de) Pyrazolcarbonsäurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE235507T1 (de) Neue aminosäurederivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE234291T1 (de) Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
ATE219069T1 (de) Neue arylglycinamidderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
ATE279392T1 (de) Indol-verbindungen, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zusammensetzungen und ihre medizinische anwendung
DE69625923D1 (de) Oxidmaterialien, verfahren zur dessen herstellung und diese materialien enthaltende katalysatorzusammensetzungen
ATE252542T1 (de) Benzolderivate, ein verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen,die diese enthalten
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE209219T1 (de) Synthetische polysaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE143010T1 (de) Pyridazin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE69933307D1 (de) Fliessfähige, wässrige borhaltige zusammensetzungen und verfahren zu ihrer herstellung
ATE222586T1 (de) Benzolsulfonamidderivate und verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE60010113D1 (de) N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
ATE313524T1 (de) 1,1- and 1,2-disubstituierte cyclopropane, verfahren zu deren herstellung und deren pharmazeutischen zusammensetzungen
DE60022890D1 (de) Naphthyridine derivate, verfahren zu ihrer herstellung, deren anwendung und sie enthaltende pharmazeutische zusammensetzungen
ATE244246T1 (de) Pyridothienodiazepine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
DE69808793D1 (de) Pharmazeutische zusammensetzungen aus dalfopristine und quinupristine und verfahren zu ihrer herstellung
DE59909123D1 (de) Neue antiestrogene, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE60200041D1 (de) Indenoindolon-Derivate, Verfahren zu ihrer Herstellung und die enthaltenden pharmazeutischen Zusammensetzungen
DE69630873D1 (de) Propylen-1-penten copolymerisate, verfahren zu deren herstellung und zusammensetzungen diese enthaltend
DE60013418D1 (de) Morpholinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
DE69421182D1 (de) Neue clathrat-verbindungen, verfahren zu ihrer herstellung und fäulmisverhinderndes mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties